Kailera Therapeutics

Hengrui's GLP-1/GIP agonist posts 18% weight loss in ph. 3 trial

Hengrui has tied its GLP-1/GIP agonist to weight loss of almost 18% at 48 weeks, leading the biotech to push for China approval “as soon as possible.”

James Waldron Jul 15, 2025 9:17am

A look at biotech's biggest money raisers of 2024

Mar 7, 2025 9:00am

Biotech's top money raisers: 2024

Mar 3, 2025 5:00am

Takeda taps Julie Kim as new CEO—Chutes & Ladders

Jan 31, 2025 8:30am